Tal Lorberbaum

Tal Lorberbaum

Titles

PhD Student in Cellular Physiology and Biophysics

As a PhD candidate in the Tatonetti Lab, my research focuses on combining biological and clinical data to elucidate mechanisms of adverse drug effects. I have developed a machine learning-based method to effectively combine observational data (e.g., adverse event reporting systems or electronic health records) with protein-protein interaction network analysis to significantly improve drug safety predictions. My goal is to continue integrating these heterogeneous "big data" sets to better understand and predict the adverse effects of drug-drug interactions. 

Before beginning my PhD studies under Dr. Tatonetti, I worked for a year as a research assistant in the lab of Andrew Marks in the Department of Physiology to uncover the structural properties of the ryanodine receptor, a calcium release channel that can be targeted pharmacologically to improve numerous cardiovascular and neurological health outcomes.

I completed a Bachelor of Science degree in biomedical engineering at California Polytechnic State University, where my work focused on computationally modeling biological phenomena as well as designing and building intuitive and cost-effective systems to aid patients and health professionals. My work was recognized by a nonprofit organization seeking to improve injured veteran quality of life as well as by Stryker Endoscopy.


Education History

MA, Columbia University
Physiology and Cellular Biophysics

BS, California Polytechnic State University
Biomedical Engineering


Publications

* indicates equal author contributions

Lorberbaum T, Sampson KJ, Chang JB, Iyer V, Woosley RL, Kass RS, Tatonetti NP. Coupling data mining and laboratory experiments to discover drug interactions causing QT prolongation. J Am Coll Cardiol. 2016 Oct 18;68(16):1756-1764.

Gayvert KM, Dardenne E, Cheung C, Boland MR, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS, Elemento O. A computational drug repositioning approach for targeting oncogenic transcription factors. Cell Rep. 2016 Jun 14;15(11):2348-56.

Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP. An integrative data science pipeline to identify novel drug interactions that prolong the QT interval. Drug Saf. 2016 Feb 10.

Boland MR*, Jacunski A*, Lorberbaum T*, Romano JD, Moskovitch R, Tatonetti NP. Systems biology approaches for identifying and understanding adverse drug events. Wiley Interdiscip Rev Syst Biol Med. 2015 Nov 12.

Vilar S, Lorberbaum T, Hripcsak G, Tatonetti NP. Improving detection of arrhythmia drug-drug interactions in pharmacovigilance data through the implementation of similarity-based modeling. PLoS One. 2015 Jun 12;10(6):e0129974.

Lorberbaum T, Nasir M, Keiser M, Vilar S, Hripcsak G, Tatonetti N. Systems pharmacology augments drug safety surveillance. Clin Pharmacol Ther. 2015 Feb;97(2):151-8.

Vilar S, Uriarte E, Santana L, Lorberbaum T, Hripcsak G, Friedman C, Tatonetti NP. Similarity-based modeling in large-scale prediction of drug-drug interactions. Nat Protoc. 2014 Sep;9(9):2147-63.


Address


Lab Staff